[go: up one dir, main page]

MX2024013590A - Adnc del antagonista del receptor de interleucina-1 - Google Patents

Adnc del antagonista del receptor de interleucina-1

Info

Publication number
MX2024013590A
MX2024013590A MX2024013590A MX2024013590A MX2024013590A MX 2024013590 A MX2024013590 A MX 2024013590A MX 2024013590 A MX2024013590 A MX 2024013590A MX 2024013590 A MX2024013590 A MX 2024013590A MX 2024013590 A MX2024013590 A MX 2024013590A
Authority
MX
Mexico
Prior art keywords
cdnas
osteoarthritis
codon
intra
compositions
Prior art date
Application number
MX2024013590A
Other languages
English (en)
Inventor
Steven C Ghivizzani
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62491596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2024013590(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2024013590A publication Critical patent/MX2024013590A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)

Abstract

La presente descripción se refiere a composiciones y métodos para el tratamiento de afecciones degenerativas de grandes articulaciones que soportan peso, tales como osteoartritis, mediante administración intra-articular de un gen que codifica IL-1Ra modificado por codón.
MX2024013590A 2016-12-07 2019-06-06 Adnc del antagonista del receptor de interleucina-1 MX2024013590A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662431336P 2016-12-07 2016-12-07
US201762486944P 2017-04-18 2017-04-18
PCT/US2017/065173 WO2018106956A2 (en) 2016-12-07 2017-12-07 IL-1RA CDNAs

Publications (1)

Publication Number Publication Date
MX2024013590A true MX2024013590A (es) 2024-12-06

Family

ID=62491596

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019006614A MX2019006614A (es) 2016-12-07 2017-12-07 Adnc del antagonista del receptor de interleucina-1.
MX2024013590A MX2024013590A (es) 2016-12-07 2019-06-06 Adnc del antagonista del receptor de interleucina-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019006614A MX2019006614A (es) 2016-12-07 2017-12-07 Adnc del antagonista del receptor de interleucina-1.

Country Status (10)

Country Link
US (2) US11958886B2 (es)
EP (1) EP3551650A4 (es)
JP (2) JP7282378B2 (es)
KR (2) KR20190088561A (es)
CN (1) CN110225923A (es)
AU (3) AU2017371043B2 (es)
BR (1) BR112019011592A2 (es)
CA (1) CA3046347A1 (es)
MX (2) MX2019006614A (es)
WO (1) WO2018106956A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230130155A (ko) * 2016-08-19 2023-09-11 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
JP7282378B2 (ja) 2016-12-07 2023-05-29 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド ＩＬ－１Ｒａ ｃＤＮＡ
BR112020014625A2 (pt) 2018-01-17 2020-12-08 Meiragtx Uk Ii Limited Proteína de capsídeo de raav modificada para terapia gênica
CN110938642B (zh) * 2018-09-25 2023-08-29 上海恒润达生生物科技股份有限公司 靶向CD123-BBz-IL1RN的嵌合抗原受体
US12370240B2 (en) 2018-11-28 2025-07-29 Genascence Corporation Methods and compositions for treating osteoarthritis
WO2020210480A2 (en) * 2019-04-10 2020-10-15 University Of Massachusetts Factor h vectors and uses thereof
LT3999119T (lt) * 2019-07-15 2024-12-10 Meiragtx Uk Ii Limited Modifikuoti aav kapsidės baltymai, skirti artritinės ligos gydymui
BR112022004906A2 (pt) * 2019-09-18 2022-06-28 Pacira Therapeutics Inc Dosagens eficazes de um sistema de liberação e expressão biológica à base de adenovírus para o uso no tratamento de osteoartrite em humanos, e composições compreendendo as mesmas
WO2024029331A1 (ja) * 2022-07-30 2024-02-08 国立大学法人 東京医科歯科大学 関節疾患の治療及び／又は予防に用いるための医薬組成物
CN117860892B (zh) * 2023-12-26 2024-08-06 武汉大学中南医院 Il-16阳性神经元在调节恐惧消退记忆中的作用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5747072A (en) 1993-07-30 1998-05-05 University Of Michigan Adenoviral-mediated gene transfer to synovial cells in vivo
JPH08508415A (ja) 1993-12-14 1996-09-10 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 結合組織疾患の全身的遺伝子治療
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
WO1998046728A1 (en) 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
CA2323726C (en) 1998-03-20 2005-02-08 Benitec Australia Ltd. Control of gene expression
DE69941905D1 (de) 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
DK1180159T3 (da) 1999-05-28 2008-11-17 Targeted Genetics Corp Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
WO2001042304A1 (en) 1999-12-10 2001-06-14 Amgen, Inc. Interleukin-1 receptor antagonist-related molecules and uses thereof
MXPA02005775A (es) 1999-12-10 2003-10-14 Amgen Inc Moleculas ralacionadas con el antagonista del receptor de la interleucina-1 y usos de las mismas.
WO2001055361A2 (en) 2000-01-26 2001-08-02 Chiron Corporation Recombinant aav packaging systems
WO2001092551A2 (en) 2000-06-01 2001-12-06 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
DE10056210A1 (de) 2000-11-13 2002-05-29 Arimedes Biotechnology Gmbh Virales Expressionssystem
WO2002062375A1 (en) 2001-02-06 2002-08-15 Merck Patent Gmbh Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
KR20030086429A (ko) 2002-05-01 2003-11-10 주식회사 제넥신 최적의 진핵 세포 발현 벡터
KR100472920B1 (ko) 2002-05-17 2005-03-08 씨제이 주식회사 고발현 효과를 갖는 ｄｎａ 백신용 벡터 및 이를 이용하여 만든 간염 백신
DE10318048A1 (de) 2003-04-17 2004-11-04 Axaron Bioscience Ag Nicht fluoreszierende, durch Proteolyse zur Fluoreszenz aktivierbare Reporterproteine und ihre Verwendung zur Detektion Protease-abhängiger Ereignisse
NZ545656A (en) 2003-09-01 2009-02-28 Amc Amsterdam AAV vectors for in vivo gene therapy of rheumatoid arthritis
US20070009899A1 (en) 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
RS57852B1 (sr) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
ES2385837T3 (es) 2004-12-15 2012-08-01 The University Of North Carolina At Chapel Hill Vectores quiméricos
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
FR2891544A1 (fr) 2005-09-30 2007-04-06 Genethon Ass Loi De 1901 Substrat proteique pour la detection de l'activite calpaine 3
US20090105148A1 (en) 2006-03-23 2009-04-23 Caritas St. Elizabeth Medical Center Of Boston, Inc. Compositions and methods for treating myocardial infarction
US20090104155A1 (en) 2006-04-21 2009-04-23 Goodrich Laurie R Treatment of connective tissue disorders
US20080187576A1 (en) 2006-06-16 2008-08-07 University Of Florida Research Foundation, Inc. Methods for treating articular disease or dysfunction using self-complimentary adeno-associated viral vectors
US20080166762A1 (en) 2006-09-27 2008-07-10 Reliance Life Science Pvt.Ltd. HETEROLOGOUS PRODUCTION OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (IL-1Ra) IN PICHIA PASTORIS
US7452696B2 (en) 2006-10-27 2008-11-18 National Taiwan University Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo
WO2008088895A2 (en) 2007-01-18 2008-07-24 University Of Missouri-Columbia Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
WO2010121010A2 (en) 2009-04-16 2010-10-21 President And Fellows Of Harvard College Methods for inhibiting starvation of a cell
MX2012003759A (es) 2009-09-29 2012-07-23 Gilead Biologics Inc Metodos y composiciones para tratamiento de fibrosis ocular.
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
WO2012047093A1 (en) 2010-10-05 2012-04-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of the sjögren's syndrome
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
US8736207B2 (en) 2011-01-03 2014-05-27 General Electric Company Method and system for power conversion
TWI531377B (zh) 2011-02-08 2016-05-01 艾伯維有限公司 骨關節炎及疼痛之治療
US20130021786A1 (en) 2011-07-21 2013-01-24 Noble Matthew D Utility bag lighting
ES2534782T3 (es) 2012-02-02 2015-04-28 Baylor College Of Medicine Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis
HK1206779A1 (en) * 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2660325A3 (en) 2012-05-02 2014-02-12 Christian Medical College AAV vectors and corresponding nucleotide sequences and methods
CN103509100B (zh) 2012-06-15 2017-10-27 上海百迈博制药有限公司 一种白细胞介素‑1受体拮抗剂突变体
US9624282B2 (en) 2012-11-26 2017-04-18 The Curators Of The University Of Missouri Microdystrophin peptides and methods for treating muscular dystrophy using the same
US20150361452A1 (en) 2013-01-25 2015-12-17 Baylor College Of Medicine A Helper-Dependent Adenoviral Gene Therapy Delivery and Expression System
CA2909706C (en) 2013-04-17 2023-02-14 Genzyme Corporation Use of an il17 inhibitor for treating and preventing macular degeneration
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
DE102013215817A1 (de) 2013-08-09 2015-02-12 Universitätsklinikum Hamburg-Eppendorf Neue peptide mit spezifität für die lunge
CA2922500A1 (en) 2013-08-27 2015-03-05 Research Institute At Nationwide Children's Hospital Products and methods for treatment of amyotrophic lateral sclerosis
WO2015044292A1 (en) 2013-09-26 2015-04-02 Universitat Autonoma De Barcelona Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
DE102013220859B4 (de) 2013-10-15 2016-09-08 Plasmidfactory Gmbh & Co. Kg Minicircles mit viralen Expressionskassetten und ihre Verwendung zur Transformation von Zellen zur Erzeugung rekombinanter Viren oder viraler Genvektoren
AU2015247777B2 (en) 2014-04-15 2019-03-21 Beacon Therapeutics Limited Codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR)
DE102014207498A1 (de) 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
PL3137497T5 (pl) 2014-05-02 2025-06-09 Genzyme Corporation Wektory AAV do terapii genowej siatkówki i OUN
KR20230130155A (ko) 2016-08-19 2023-09-11 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
EP3503928A4 (en) 2016-08-19 2020-03-18 Colorado State University Research Foundation METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANINE CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS.
US20210283222A1 (en) 2016-08-19 2021-09-16 Calimmune, Inc. Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
JP7282378B2 (ja) 2016-12-07 2023-05-29 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド ＩＬ－１Ｒａ ｃＤＮＡ

Also Published As

Publication number Publication date
JP7282378B2 (ja) 2023-05-29
JP2023078402A (ja) 2023-06-06
AU2017371043B2 (en) 2022-12-15
JP2019536465A (ja) 2019-12-19
AU2023201531A1 (en) 2023-04-13
WO2018106956A2 (en) 2018-06-14
KR20190088561A (ko) 2019-07-26
CN110225923A (zh) 2019-09-10
MX2019006614A (es) 2019-10-15
KR20250121159A (ko) 2025-08-11
US11958886B2 (en) 2024-04-16
US20200071371A1 (en) 2020-03-05
BR112019011592A2 (pt) 2019-10-22
AU2025230804A1 (en) 2025-10-02
EP3551650A2 (en) 2019-10-16
WO2018106956A3 (en) 2018-07-12
EP3551650A4 (en) 2020-07-08
US20240327479A1 (en) 2024-10-03
CA3046347A1 (en) 2018-06-14
AU2017371043A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
MX2024013590A (es) Adnc del antagonista del receptor de interleucina-1
MX2017007538A (es) Sintesis de ácido nucleíco de volúmen pequeño, alta eficiencia.
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
UA117289C2 (uk) Мультиспецифічне антитіло
PH12020500329A1 (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
EP4349404A3 (en) Respiratory virus vaccines
MX2017005784A (es) Dextranos gelificantes enzimaticamente polimerizados.
PH12017501035A1 (en) Method for the production of a pharmaceutical delivery system
AU2014375265A1 (en) Novel pyrazolyl-heteroarylamides as pesticides
BR112017005997A2 (pt) método
MX2017014035A (es) Formas solidas novedosas.
WO2015198240A3 (en) Compositions and methods for long acting proteins
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
AU2015261096A8 (en) Process for preparing phosphorus-containing cyanohydrins
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
MY183061A (en) Polypeptides having xylanase activity with a high conversion rate of xylose-containing polysaccharides
PH12016501613B1 (en) Pyrazines modulators of gpr6
EP3141573A4 (en) Curable polysilsesquioxane compound, production method thereof, curable composition, cured product and use method of curable composition, etc.
MX376061B (es) Anticuerpos contra antìgeno de plaqueta 1a humano (hpa-1a).
EA201790321A1 (ru) Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
MX2018007018A (es) Polimero de multiples etapas como aditivo de molienda y metodo de produccion del mismo.
JO3712B1 (ar) طريقة لتحضير 1-(4-ميثان سلفونيل-2-تراي فلورو ميثيل-بنزيل)-2ميثيل-1h-بيرولو[2، 3-b]بيريدين-3-يل-حمض أسيتيك
SG10201803880TA (en) Stable compositions of neuroactive peptides
MX2017008776A (es) Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario.